Northwire Canada EditionFriday, July 17, 2026
Sign inSubscribe
Northwire
⌕
FFU 0.125 +4.2% TVI 0.040 −20.0% ZNX 0.080 +0.0% TSK 1.05 +0.5% SFR 0.370 +68.2% OMM 0.050 +0.0% EMO 0.330 −4.3% GGA 5.24 −1.1% MDM 0.060 +0.0% WGX 4.29 −3.3% FL 0.410 +0.0% SSRM 35.69 −1.8% CD 0.245 +6.5% GEN 0.065 −7.1% ALS 55.26 −3.8% LIFT 3.35 +6.3% FFU 0.125 +4.2% TVI 0.040 −20.0% ZNX 0.080 +0.0% TSK 1.05 +0.5% SFR 0.370 +68.2% OMM 0.050 +0.0% EMO 0.330 −4.3% GGA 5.24 −1.1% MDM 0.060 +0.0% WGX 4.29 −3.3% FL 0.410 +0.0% SSRM 35.69 −1.8% CD 0.245 +6.5% GEN 0.065 −7.1% ALS 55.26 −3.8% LIFT 3.35 +6.3%
Financings

PharmaCorp Announces Closing of C$23 Million Bought Deal Public Offering

By The Northwire Desk — AI Analysis Nov 12, 2025 · 09:28 PCRX · 0.43 PharmaCorp Rx Inc.
PCRX · Price

Executive Summary

  • PharmaCorp Rx Inc. closed a bought‑deal public offering of 54,855,000 units at C$0.42 per unit, generating approximately C$23.0 million in gross proceeds.
  • The net proceeds are earmarked for future pharmacy acquisition opportunities and general working capital, supporting the company’s growth strategy.
  • Underwriters received a cash commission of 6.0% of gross proceeds (≈ C$1.13 M) plus 2,026,130 broker warrants exercisable at C$0.42 per unit; related‑party directors purchased 3,762,010 units under the same terms.

Key Details

  • Offering Structure:
  • 54,855,000 units sold (including full over‑allotment).
  • Each unit = 1 common share + ½ common‑share purchase warrant.

  • Warrants allow acquisition of one common share at C$0.50 until 12 Nov 2027; listing on TSXV under “PCRX.WT” pending final acceptance.

  • Pricing & Proceeds:

  • Offering price: C$0.42 per unit.

  • Gross proceeds: ≈ C$23.0 million.

  • Use of Proceeds:

  • Targeted for future pharmacy acquisitions and general working capital to accelerate national growth.

  • Related‑Party Participation:

  • Directors/officers purchased 3,762,010 units, qualifying as a related‑party transaction under TSX Venture policies; exemptions applied per MI 61‑101. No change of control or new insiders created.

  • Underwriter Compensation:

  • Cash commission: 6.0% of gross proceeds (≈ C$1,134,633).
  • Reduced 3.0% commission on “president’s list” sales; no commission on certain insider purchases.

  • Issuance of 2,026,130 broker warrants (exercise price C$0.42 per unit, exercisable until 12 Nov 2026).

  • Regulatory Filings:

  • Units offered via prospectus supplement dated 7 Nov 2025 to the short‑form base shelf prospectus filed 14 Oct 2025.

  • Prospectus documents available on SEDAR+ and through underwriters’ contacts.

  • Forward‑Looking Statements:

  • Anticipated warrant trading on TSXV, continued acquisition of PharmaChoice Canada‑bannered and independent pharmacies, and execution of the national growth strategy.

Notable Quotes

(No direct quotes were provided in the release.)

Read the original news release →

More from PharmaCorp Rx Inc.

Jun 29, 2026 · 07:16

PharmaCorp Announces Definitive Agreement to Acquire Western Canada PharmaChoice Bannered Pharmacy

M&A / Property Jun 01, 2026 · 09:00

PharmaCorp Rx Inc. Consolidates Eastern Canada Footprint as Q1 Revenue Surges 79%, Yet Margin Compression and Integration Pace Demand Caution

Earnings May 25, 2026 · 09:27

PharmaCorp Rx Advances National Footprint with Definitive Acquisition, Pipeline Execution Validates Growth Strategy

M&A / Property May 01, 2026 · 17:00

PharmaCorp Rx Inc.

M&A / Property Apr 30, 2026 · 11:04

PharmaCorp Doubles Footprint, Cash Reserves Depleted by Aggressive Buyout

M&A / Property Apr 29, 2026 · 20:51

PharmaCorp Rx Confirms M&A Execution but Stock Stalls Near Dilutive Offering Price

Earnings